AlzeCure Pharma announced positive results from its first clinical study of ACD856 for the potential treatment of Alzheimer’s disease. According to the company, ACD856 showed a good pharmacokinetic profile — namely a significantly shorter human half-life than its predecessor, ACD855 — and suitability for further clinical development as an oral medication for Alzheimer’s. Pharmacokinetics refers, essentially, to how the body affects a medicine. The half-life of a compound refers to how long it takes for…
You must be logged in to read/download the full post.
The post AlzeCure Announces Positive Data From Its First Clinical Study of ACD856 appeared first on BioNewsFeeds.